Profil Penggunaan Obat-Antituberkulosis dan Anti-Retroviral pada Pasien Tuberkulosis-HIV Periode 2024-2025

Dinda Shafa Nabila (Prodi Farmasi, Fakultas Farmasi dan Sains, Universitas Islam Bandung, Indonesia)
Bambang Tri Laksono (Prodi Farmasi, Fakultas Farmasi dan Sains, Universitas Islam Bandung, Indonesia)
Umi Yuniarni (Prodi Farmasi, Fakultas Farmasi dan Sains, Universitas Islam Bandung, Indonesia)

Bandung Conference Series: Pharmacy
779 - 788

Abstract. Tuberculosis (TB) is an opportunistic infection that frequently occurs in patients with Human Immunodeficiency Virus (HIV), requiring concurrent treatment with antituberculosis drugs (OAT) and antiretroviral drugs (ARV). This study aims to describe the characteristics of patients as well as the usage profiles of OAT, ARVs, and supportive medications among TB-HIV patients at Hospital X during the 2024–2025 period. The study employed a descriptive observational method with a retrospective approach based on medical record data. The sample was obtained using total sampling and included 75 patients who met the study criteria. Descriptive analysis was performed using frequency distributions and percentages. The results showed that the majority of patients were male (73.33%), aged 18–59 years (98.67%), and had extrapulmonary TB (61.33%). All patients received fixed-dose combination anti-tuberculosis therapy (2RHZE/4RH). The most commonly used ARV regimen was Tenofovir/Lamivudine/Efavirenz (TLE) (65.33%), followed by Tenofovir/Lamivudine/Dolutegravir (TLD) (29.33%). The most frequently administered adjunctive medications were vitamin B6 (74.67%) and co-trimoxazole (72.00%). The study results indicate that the use of OAT and ARVs was in accordance with national guidelines, with vitamin B6 and co-trimoxazole being the most commonly used adjunctive therapies. Abstrak. Tuberkulosis (TB) merupakan infeksi oportunistik yang sering terjadi pada pasien Human Immunodeficiency Virus (HIV), sehingga memerlukan terapi obat anti-tuberkulosis (OAT) dan antiretroviral (ARV) secara bersamaan. Penelitian ini bertujuan menggambarkan karakteristik pasien serta profil penggunaan OAT, ARV, dan obat pendukung pada pasien TB-HIV di Rumah Sakit X periode 2024–2025. Penelitian menggunakan metode observasional deskriptif dengan pendekatan retrospektif berdasarkan data rekam medis. Sampel diperoleh menggunakan metode total sampling dan melibatkan 75 pasien yang memenuhi kriteria penelitian. Analisis dilakukan secara deskriptif menggunakan distribusi frekuensi dan persentase. Hasil penelitian menunjukkan bahwa mayoritas pasien berjenis kelamin laki-laki (73,33%), berusia 18–59 tahun (98,67%), dan mengalami TB ekstraparu (61,33%). Seluruh pasien menerima OAT kombinasi dosis tetap (2RHZE/4RH). Regimen ARV yang paling banyak digunakan adalah Tenofovir/Lamivudin/Efavirenz (TLE) (65,33%), diikuti Tenofovir/Lamivudin/Dolutegravir (TLD) (29,33%). Obat pendukung yang paling sering diberikan adalah vitamin B6 (74,67%) dan kotrimoksazol (72,00%). Hasil penelitian menunjukkan bahwa penggunaan OAT dan ARV telah sesuai dengan pedoman nasional, dengan vitamin B6 dan kotrimoksazol sebagai terapi pendukung yang paling banyak digunakan.